Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

• Main Authors: David Pérez Compte (Author), Lucas Etourneau (Author), Anne-Marie Hesse (Author), Alexandra Kraut (Author), Justine Barthelon (Author), Nathalie Sturm (Author), Hélène Borges (Author), Salomé Biennier (Author), Marie Courçon (Author), Marc de Saint Loup (Author), Victoria Mignot (Author), Charlotte Costentin (Author), Thomas Burger (Author), Yohann Couté (Author), Christophe Bruley (Author), Thomas Decaens (Author), Michel Jaquinod (Author), Jérôme Boursier (Author), Virginie Brun (Author)
• Format: Book
• Published: BMC, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 30% of the world's population, and its prevalence is increasing in line with obesity. Liver fibrosis is closely related to mortality, making it the most important clinical parameter for M...